tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
PremiumRatingsSavara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
2M ago
Savara resubmits Molbreevi BLA to the FDA
Premium
The Fly
Savara resubmits Molbreevi BLA to the FDA
2M ago
Savara announces EPO intention to grant Molbreevi patent application
Premium
The Fly
Savara announces EPO intention to grant Molbreevi patent application
2M ago
Savara Inc. Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsSavara Inc. Reports Q3 2025 Financial Results
3M ago
Savara price target raised to $9 from $8 at Oppenheimer
Premium
The Fly
Savara price target raised to $9 from $8 at Oppenheimer
3M ago
Savara’s Strategic Positioning and Market Readiness for Molbreevi’s Potential Launch
Premium
Ratings
Savara’s Strategic Positioning and Market Readiness for Molbreevi’s Potential Launch
3M ago
Savara Announces $130 Million Public Offering
PremiumCompany AnnouncementsSavara Announces $130 Million Public Offering
4M ago
Savara 23.81M share Spot Secondary priced at $4.20
Premium
The Fly
Savara 23.81M share Spot Secondary priced at $4.20
4M ago
Savara Announces $75M Royalty Funding Agreement
Premium
Company Announcements
Savara Announces $75M Royalty Funding Agreement
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100